Prostate cancer (PCa) is the second leading cause of cancer related death in men in the United States, suggesting that novel molecular targets as well as the development of agents that could deregulate such targets would become newer therapeutic approach for the treatment of castrate resistant prostate cancer (CRPC) especially the metastatic CRPC (mCRPC). In search for novel targets, microRNAs (miRNAs) are becoming an emerging area because miRNAs function as regulators of gene expression in human cancers including PCa. Previous studies from our laboratory have shown that the expression of miR-34a is significantly down-regulated in human PCa specimens consistent with PCa cell lines with aggressive characteristics, and that the silencing of miR-34a expression was in part due to hypermethylation of its promoter. There are several genes that are direct targets of miR-34a, and in the current study we investigated the cellular consequence of miR-34a over-expression and under-expression in the regulation of androgen receptor (AR) and Notch-1 in PCa cells. We found that over-expression of miR-34a led to reduced expression of AR, PSA and Notch-1. We also found that over-expression of miR-34a significantly inhibited the growth of PCa cells. Moreover, over-expression of miR-34a resulted in decreased self-renewal capacity of PCa cells, and conversely inactivation of miR-34a led to increased self-renewal capacity, which is an indication of tumor cell aggressiveness. These findings suggest that the loss of miR-34a is directly linked with up-regulation of AR and Notch-1 both of which are highly expressed in PCa, and thus finding innovative approaches by which miR-34a expression could be up-regulated will have a huge impact on the treatment of PCa especially for the treatment of mCRPC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493023 | PMC |
Ann Intern Med
January 2025
Durham VA Health Care System, Durham; and Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina (K.M.G.).
Background: Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations.
Purpose: To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions on treatment choice among patients with localized PCa considering first-line treatment.
Data Sources: MEDLINE, EMBASE, and Web of Science published from January 2010 to August 2024.
Ann Intern Med
January 2025
Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
Oncologist
January 2025
Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada.
Background: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis, necessitating the investigation of novel treatments and targets. This study evaluated JNJ-70218902 (JNJ-902), a T-cell redirector targeting transmembrane protein with epidermal growth factor-like and 2 follistatin-like domains 2 (TMEFF2) and cluster of differentiation 3, in mCRPC.
Patients And Methods: Patients who had measurable/evaluable mCRPC after at least one novel androgen receptor-targeted therapy or chemotherapy were eligible.
Mol Biotechnol
January 2025
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Opioids are the primary regimens for perioperative analgesia with controversial effects on oncological survival. The underlying mechanism remains unexplored. This study developed survival-related gene co-expression networks based on RNA-seq and clinical characteristics from TCGA cohort.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!